Literature DB >> 11745192

Endometrioid adenocarcinomas of the uterine corpus in women younger than 50 years of age can be divided into two distinct clinical and pathologic entities based on anatomic location.

T Hachisuga1, K Fukuda, T Iwasaka, T Hirakawa, T Kawarabayashi, M Tsuneyoshi.   

Abstract

BACKGROUND: This study used the clinicopathologic profiles of Japanese women younger than 50 years of age with endometrial carcinoma to distinguish the clinicopathologic features of carcinomas of the lower uterine segment (LUS) from those of carcinomas of the corpus mucosa proper (CMP).
METHODS: Eighty-eight endometrial carcinomas in women younger than 50 years old (25.3%) were selected from our file of 348 Japanese women with endometrial carcinoma. Seventy-two were classified as carcinomas of the CMP and 16 carcinomas of the LUS. A tumor was judged to be a carcinoma of the LUS when it involved a continuous area ranging from the lower corpus to the upper cervix with or without intervention of a portion of uninvolved LUS.
RESULTS: The mean ages of women with carcinomas of the CMP and LUS were 41.2 and 39.0 years, respectively. In comparison to carcinomas of the LUS, carcinomas of the CMP were more strongly associated with reproductive risk factors including parity (P = 0.01) and polycystic ovary syndrome (P = 0.02). There was no significant difference in body mass index or the incidence of diabetes mellitus and hypertension between women presenting with carcinomas of the CMP and LUS. Histologically, carcinomas of the LUS more frequently showed a high-grade endometrioid tumor (P = 0.02) with deep myometrial invasion (P < 0.01) and were less associated with endometrial hyperplasia (P < 0.01) than those of the CMP.
CONCLUSIONS: Carcinomas of the LUS occurred predominantly in women younger than 50 years of age and had clinicopathologic features distinct from carcinomas of the CMP in women younger than 50 years of age. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Year:  2001        PMID: 11745192     DOI: 10.1002/1097-0142(20011115)92:10<2578::aid-cncr1610>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome.

Authors:  Shannon N Westin; Robin A Lacour; Diana L Urbauer; Rajyalakshmi Luthra; Diane C Bodurka; Karen H Lu; Russell R Broaddus
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

2.  Carcinoma of the Lower Uterine Segment (LUS): Clinicopathological Characteristics and Association with Lynch Syndrome.

Authors:  Kenta Masuda; Kouji Banno; Megumi Yanokura; Yusuke Kobayashi; Iori Kisu; Arisa Ueki; Asuka Ono; Hiroyuki Nomura; Akira Hirasawa; Nobuyuki Susumu; Daisuke Aoki
Journal:  Curr Genomics       Date:  2011-03       Impact factor: 2.236

3.  Clear cell carcinoma of the lower uterine segment: A case report.

Authors:  Yusuke Matoba; Iori Kisu; Keiko Saotome; Motoko Katayama; Makiko Taniguchi; Yumiko Miura; Taeko Goto; Nobumaru Hirao
Journal:  Mol Clin Oncol       Date:  2016-10-11

4.  Prognostic factors for patients with early-stage uterine serous carcinoma without adjuvant therapy.

Authors:  Keisei Tate; Hiroshi Yoshida; Mitsuya Ishikawa; Takashi Uehara; Shun Ichi Ikeda; Nobuyoshi Hiraoka; Tomoyasu Kato
Journal:  J Gynecol Oncol       Date:  2018-02-19       Impact factor: 4.401

5.  Grade 3 endometrioid adenocarinoma of the lower uterine segment diagnosed 6 weeks after a term delivery: A case report and literature review.

Authors:  Zoe Laing-Aiken; Sara Ooi; Gaithri Mylvaganam; Huan Xie; Joanne Ludlow; Selvan Pather
Journal:  Gynecol Oncol Rep       Date:  2021-10-15

6.  Relationship of lower uterine segment cancer with Lynch syndrome: a novel case with an hMLH1 germline mutation.

Authors:  Kenta Masuda; Kouji Banno; Akira Hirasawa; Megumi Yanokura; Kosuke Tsuji; Yusuke Kobayashi; Iori Kisu; Arisa Ueki; Hiroyuki Nomura; Eiichiro Tominaga; Nobuyuki Susumu; Daisuke Aoki
Journal:  Oncol Rep       Date:  2012-08-31       Impact factor: 3.906

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.